.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Fuji
Cipla
US Army
Covington
UBS
QuintilesIMS
Express Scripts
Federal Trade Commission

Generated: December 16, 2017

DrugPatentWatch Database Preview

Tedizolid phosphate - Generic Drug Details

« Back to Dashboard

What are the generic sources for tedizolid phosphate and what is the scope of tedizolid phosphate patent protection?

Tedizolid phosphate
is the generic ingredient in one branded drug marketed by Cubist Pharms Llc and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tedizolid phosphate has seventy-one patent family members in thirty-seven countries and thirteen supplementary protection certificates in nine countries.

One supplier is listed for this compound.

Summary for tedizolid phosphate

Pharmacology for tedizolid phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphateTABLET;ORAL205435-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► SubscribeYY► Subscribe
Cubist Pharms LlcSIVEXTROtedizolid phosphatePOWDER;IV (INFUSION)205436-001Jun 20, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: tedizolid phosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,624,250Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate► Subscribe
9,163,043Oxazolidinone derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: tedizolid phosphate

Country Document Number Estimated Expiration
Mexico339597► Subscribe
Philippines12014500092► Subscribe
Luxembourg92834► Subscribe
MexicoPA06006955► Subscribe
BrazilPI0417800► Subscribe
LithuaniaC1699784► Subscribe
Netherlands300759► Subscribe
Cyprus1112445► Subscribe
EcuadorSP11011285► Subscribe
Portugal1699784► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TEDIZOLID PHOSPHATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0062France► SubscribePRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325
3 50021-2015Slovakia► SubscribePRODUCT NAME: TEDIZOLIDFOSFAT; REGISTRATION NO/DATE: EU/1/15/991/001 - EU/1/15/991/003 20150325
0762Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323
0759Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE VORM VAN EEN ESTER, IN HET BIJZONDER EEN FOSFAAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015000078Germany► SubscribePRODUCT NAME: TEDIZOLID, GEGEBENENFALLS IN FORM EINES ESTERS, INSBESONDERE EINES PHOSPHATS, ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/991/001-003 20150323
2015 00048Denmark► SubscribePRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325
2015032Lithuania► SubscribePRODUCT NAME: TEDIZOLIDO FOSFATAS; REGISTRATION NO/DATE: EU/1/15/991 20150323
90047-5Sweden► SubscribePRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325
834Luxembourg► SubscribePRODUCT NAME: TEDIZOLIDE, OPTIONNELLEMENT SOUS LA FORME D UN ESTER, EN PARTICULIER UN PHOSPHATE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150325
00759Netherlands► SubscribePRODUCT NAME: TEDIZOLID, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/15/991 20150323
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
McKinsey
Johnson and Johnson
QuintilesIMS
US Department of Justice
Merck
Express Scripts
Daiichi Sankyo
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot